{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Degarelix+%26+Relugolix", "query": { "intervention": "Degarelix & Relugolix" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Degarelix+%26+Relugolix&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T23:18:16.681Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07455903", "title": "Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Localized Prostate Carcinoma" ], "interventions": [ { "name": "Leuprolide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "18-F Flotufolastat PSMA PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Radical prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2026-07-29", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07455903" }, { "nct_id": "NCT06922318", "title": "The COSMYC Trial (COmbined Suppression of MYC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "ZEN-3694", "type": "DRUG" }, { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2025-08-19", "completion_date": "2031-08-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06922318" }, { "nct_id": "NCT04513717", "title": "Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Buserelin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2753, "start_date": "2021-01-21", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 594, "location_summary": "Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04513717" }, { "nct_id": "NCT07142551", "title": "Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-03-09", "completion_date": "2034-06-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07142551" }, { "nct_id": "NCT06059118", "title": "Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "DFMO", "type": "DRUG" }, { "name": "testosterone cypionate", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2023-10-04", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06059118" }, { "nct_id": "NCT06531499", "title": "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) antagonists", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 106, "start_date": "2024-11-11", "completion_date": "2028-11-24", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06531499" }, { "nct_id": "NCT06734130", "title": "Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Sensitive Prostate Cancer" ], "interventions": [ { "name": "Luteinizing Hormone-Releasing Hormone (LHRH) analog", "type": "DRUG" }, { "name": "Androgen Receptor Signal Inhibitor (ARSI)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2025-01-10", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06734130" }, { "nct_id": "NCT05189457", "title": "First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Luteinizing Hormone Releasing Hormone", "type": "DRUG" }, { "name": "New Hormonal Agent", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2022-01-25", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05189457" }, { "nct_id": "NCT05050084", "title": "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Buserelin", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2050, "start_date": "2021-12-06", "completion_date": "2031-11-11", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 567, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050084" }, { "nct_id": "NCT06379217", "title": "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neuroendocrine Prostate Cancer" ], "interventions": [ { "name": "[68Ga]Ga-PSMA-11", "type": "DRUG" }, { "name": "[68Ga]GA-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-PSMA-617", "type": "DRUG" }, { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "L-Lysine HCl-L-Arginine HCl, 2.5 %,", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "GnRH antagonists", "type": "DRUG" }, { "name": "Antiemetics & antinauseants", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 31, "start_date": "2024-07-29", "completion_date": "2026-09-11", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-26T23:18:16.681Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06379217" } ] }